AstraZeneca PLC (AZNCF)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
At close: 03:05PM EDT
| Previous close | 125.49 |
| Open | 122.09 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 122.09 - 125.90 |
| 52-week range | 105.26 - 143.90 |
| Volume | |
| Avg. volume | 2,517 |
| Market cap | 198.169B |
| Beta (5Y monthly) | 0.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.72 |
| Earnings date | N/A |
| Forward dividend & yield | 2.81 (2.23%) |
| Ex-dividend date | 24 Feb 2022 |
| 1y target est | N/A |
- Zacks
Merck (MRK) Outperforms Industry This Year So Far: Here's Why
Strong sales of key products like Keytruda and Gardasil, a significant contribution from Lagevrio and positive pipeline/regulatory developments have been keeping Merck's (MRK) stock afloat in 2022.
- Zacks
AstraZeneca (AZN) Inks Deal to Develop COVID-19 Antibodies
AstraZeneca (AZN) partners with a U.K.-based biotech company to develop monoclonal antibodies targeting the COVID-causing virus.
- Business Wire
PT027, a Novel Fixed-Dose Combination of Albuterol and Budesonide, Used as an As-Needed Rescue Medicine, Significantly Reduced the Risk of a Severe Exacerbation Compared to Albuterol by 27% in Patients With Asthma
WILMINGTON, Del., May 15, 2022--Full results from the positive MANDALA Phase III trial showed that PT027 (albuterol/budesonide) at two different strengths of budesonide, an inhaled corticosteroid (ICS), used as an as-needed rescue medicine, demonstrated a statistically significant reduction in the risk of a severe exacerbation versus albuterol rescue in patients with moderate to severe asthma.1,2
© 2022 Yahoo. All rights reserved.
